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ORIGINAL RESEARCH

Formulating a Treatment Plan in
Suspected Lymphoma
Ultrasound-Guided Core Needle Biopsy Versus Core Needle
Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes
Monica R. Drylewicz, MD, PhD , Marcus P. Watkins, PhD, Anup S. Shetty, MD, Michael F. Lin, MD,
Amber Salter, PhD, Nancy L. Bartlett, MD, William D. Middleton, MD, Motoyo Yano, MD, PhD
Objectives—Image-guided tissue sampling in the workup of suspected lymphoma can be performed by core needle biopsy (CNB) or CNB with ﬁne-needle
aspiration (FNA). We compared the yield of clinically actionable diagnoses
between these methods of tissue sampling.
Methods—All ultrasound-guided percutaneous peripheral lymph node biopsies from
2010 to 2017 at a single institution were retrospectively reviewed for biopsy type
(CNB versus CNB + FNA), prior diagnosis of lymphoma, size of the target lymph
node, number of cores, length of core specimens, and pathologic diagnosis. Lymphoma and lymphoid tissue were included; metastatic disease and nonlymphoid tissue were excluded. An oncologist specializing in lymphoma independently
determined whether an actionable diagnosis could be made with the pathologic
results in the context of the patient’s medical record. χ2 analyses and univariable/
multivariable logistic regression models were used for statistical analyses.
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Results—Of 578 lymph node biopsies, 306 (53%) had a prior diagnosis of lymphoma; 273 (47%) were CNB, and 305 (53%) were CNB + FNA. There was
no signiﬁcant difference between biopsy types (CNB versus CNB + FNA) in
the number of cores (median [25th, 75th percentiles], 3 [3, 4] versus 4 [3, 4];
P = .47) or total length of tissue (4.1 [2.5, 6.1] versus 3.7 [2.3, 6] cm; P = .09).
There was no difference in obtaining an actionable diagnosis between biopsy
types after controlling for a known history of lymphoma (P = .271) or after controlling for the number of core specimens (P = .826).
Conclusions—In cases of suspected lymphoma, CNB without FNA was sufﬁcient
to obtain an actionable diagnosis.
Key Words—biopsy; core; ﬁne-needle aspiration; lymphoma; ultrasound guided

L

ymphoma is a broad category of diseases encompassing
malignancies of the lymphocyte (B cells and T cells). There
are more than 50 different subtypes of lymphoma in the most
recent classification system,1 the treatment and prognosis of which vary
considerably. Patients may present with vague symptoms such as lowgrade fever and weight loss, palpable lymphadenopathy, or altered
hematologic laboratory values. The diagnostic evaluation for lymphoma requires tissue for determination of the presence of lymphoma and
disease subclassification to formulate a treatment plan.1
Multiple methods may be used to obtain tissue for histopathologic analysis, including excisional/incisional biopsy and image-guided
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percutaneous tissue sampling by core needle biopsy
(CNB) or ﬁne-needle aspiration (FNA).2,3 Although
there is no clear recommendation by the American Cancer Society as of 2016, the European Society of Medical
Oncology recommends surgical excision whenever possible.4 However, in our experience, many physicians,
including those with expertise in lymphoma, prefer percutaneous biopsy given its less-invasive nature, ease of
scheduling, lower cost, and generally high yield of diagnostic data. Core needle biopsy uses a spring-loaded
side notch or hollow-bore needle to obtain a solid core
of tissue from the target lesion. Fine-needle aspiration
uses multiple small-gauge needles with rapid back-andforth motion in the target lesion to collect individual
cells in the needle tip. Core biopsies, when intact, retain
some architectural context, whereas FNA loses all such
tissue information, relying solely on individual cellular
characteristics for diagnosis.5
There is a large volume of literature investigating
the diagnostic yield of tissue sampling in the setting
of suspected lymphoma. Many of these studies have
addressed whether image-guided biopsy performs
adequately compared to excisional biopsy in the diagnosis and treatment of lymphoma.4,6–8 Fine-needle
aspiration alone is clearly inadequate compared to
excisional biopsy.2,9 The success rate of CNB alone in
yielding a clinically actionable diagnosis ranges from
67% to 100%.6,7,10–18 Some of the highest yields considered only patients with a history of lymphoma
(90%–97%)7,10,13 or reported the success rate of subclassiﬁcation when lymphoma was diagnosed on the
biopsy (100%).12 In our practice, CNB and FNA of
the same target lesion are often requested and performed to collect tissue for histopathologic analysis
and ﬂow cytometry. However, performing both CNB
and FNA increases the procedural time as well as cost
and, potentially, patient anxiety. We performed this
study given the paucity of data comparing the actionable yield of CNB compared to CNB + FNA.

Materials and Methods
A cohort of patients with lymphadenopathy biopsied
with ultrasound guidance at our institution between
July 1, 2010 and December 31, 2016, was retrospectively reviewed. The patient cohort was obtained by a
Health Insurance Portability and Accountability Act–
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compliant, Institutional Review Board–approved
search of our institutional radiology database, Montage (Nuance Communications, Burlington, MA).
Informed consent was waived by the Institutional
Review Board. Biopsy of superﬁcial lymphadenopathy
was performed by searching for studies given a Current Procedural Terminology code for needle biopsy of
lymph nodes (code 38505) exclusive of breast.
Excluding the term “breast” was done to eliminate
the large number of axillary lymph node biopsies performed to diagnose metastatic breast cancer. For
patients with multiple biopsies, whether it be on the
same or different dates, only the ﬁrst biopsy performed was included for analysis. Therefore, each
biopsy corresponded to an individual patient. Biopsies
performed for research, those without a ﬁnal pathology report, those coded incorrectly, and those yielding a diagnosis of metastasis, another mass, or no
lymphoid tissue were excluded.
Several data points were collected for each biopsy
and are detailed in Table 1. These data points included
patient sex, age, date of biopsy, whether the patient had
a prior diagnosis of lymphoma, location of the biopsy,
largest dimension of the target lesion, type of biopsy
performed (CNB or CNB + FNA), CNB gauge, and
number of CNB passes. Core needle biopsy specimens
were placed in formalin and submitted to surgical
pathology for interpretation. Fine-needle aspiration
specimens were submitted in RPMI solution for ﬂow
cytometry with the assistance of our sonographers. No
pathologist was present at the time of CNB or FNA.
Reported complications of the procedure were
recorded. Minimum and maximum lengths of the core
samples received by pathology and the pathologic diagnosis were recorded. The total length of CNB tissue
was estimated as follows: [(number of cores –
1) × maximum core length recorded by pathology] +
minimum core length recorded by pathology.
The hematology/oncology team specializing in
lymphoma then independently reviewed the pathologic
diagnosis as well as other available data from the
patient’s medical record. A binary decision was rendered, determining whether the diagnosis was actionable. A diagnosis was considered actionable if the
pathologic diagnosis considered within the context of
the patient allowed either for initiation of treatment or
ﬁnal determination of benignity requiring no further
intervention.
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Results

Table 1. Patient and Biopsy Statistics
Variable

CNB

CNB + FNA

P

Patients, n
Age, y

273
62 [49, 70]
(19–92)

305
54 [39, 65]
(19–93)

<.0001

160 (58.6)
113 (41.1)

163 (53.4)
142 (46.6)

Sex, n (%)
Male
Female
Prior lymphoma
diagnosis, n (%)
No
Yes
Biopsy location, n (%)
Cervical/
supraclavicular
Inguinal
Axillary
Other
Maximum target
size, cm
CNB gauge, n (%)
16
18
20
Cores, n (%)
1–2
3
4
≥5
Cores, n
Estimated length, cm

.212

<.0001
63 (23.1)
210 (76.9)

208 (68.2)
97 (31.8)
.0008

95 (34.8)

150 (49.2)

86 (31.5)
84 (30.8)
8 (2.9)
3.3 [2.2, 4.1]
(0.9–14.1)

82 (26.9)
67 (22.0)
6 (2.0)
3.2 [2.1, 4.0]
(1.0–10.2)

19 (6.9)
253 (92.7)
1 (0.4)

21 (6.8)
282 (92.4)
2 (0.6)

67 (24.5)
79 (28.9)
60 (22.0)
67 (24.5)
3 [3, 4] (1–8)
4.1 [2.5, 6.1]
(0.4–24.8)

61 (20.0)
88 (28.8)
111 (36.4)
45 (14.8)
4 [3, 4] (1–7)
3.7 [2.3, 6.0]
(0.7–20.9)

.5
.889

.47
.09

Data are presented as median [25th, 75th percentiles] (range)
where applicable. Statistical signiﬁcance was determined by the
Wilcoxon rank sum test for continuous variables and the χ2 test for
categorical variables.

Descriptive statistics were used to summarize
patient and biopsy characteristics using medians [25th,
75th percentiles] for continuous variables and frequency (percent) for categorical variables. Differences
in characteristics and actionable diagnoses between
CNB and CNB + FNA were compared by Wilcoxon
rank sum or χ2 square tests as appropriate. A CochranMantel-Haenszel test was used to evaluate the association of an actionable diagnosis and biopsy controlling
for a history of lymphoma. The association between
the number of cores and target size was evaluated by a
Spearman correlation. Multivariable logistic regression
models were used to evaluate the association of the
number of cores and CNB gauge with an actionable
diagnosis. Statistical analyses were performed with SAS
version 9.4 software (SAS Institute Inc, Cary, NC).
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The initial search yielded 908 superﬁcial lymph node
biopsies performed with ultrasound guidance. A total
of 25 biopsies were performed for research; 13 were
incorrectly coded; and 12 were missing pathologic
results. A total of 858 biopsies were analyzed:
259 yielded metastatic disease; 6 yielded a diagnosis
of another mass (1 Warthin tumor, 3 peripheral nerve
sheath tumors, 1 myoepithelial cyst, and 1 lymphoepithelial cyst); and 15 showed no lymphoid tissue
(generally showing necrosis or muscle on pathologic
specimens). These were excluded from the analysis. A
total of 578 biopsies yielded a diagnosis of lymphoma
or benign/indeterminate lymphoid tissue and were
further analyzed by our oncology team.
Of the 578 biopsies used for analysis, 273 were
CNB, and 305 were CNB + FNA (Table 1). These
patient populations were similar in sex distribution
(58.6% versus 53.4% male, respectively). Patients undergoing CNB alone were signiﬁcantly older than patients
undergoing CNB + FNA (62 [49, 70] versus
54 [39, 65] years, respectively; P < .01). When comparing the proportion of patients with a history of lymphoma between the biopsy types, more patients
undergoing CNB alone had a prior diagnosis of lymphoma compared to those undergoing CNB + FNA
(76.9% versus 31.8%; P < .01). Biopsied peripheral
lymph node locations were cervical/supraclavicular
(34.8% of CNB versus 49.2% of CNB + FNA), inguinal
(31.5% of CNB versus 26.9% of CNB + FNA), and
axillary (30.8% of CNB versus 22.0% of CNB + FNA).
Most CNB specimens were obtained with an 18-gauge
needle. There was no difference in the median [25th,
75th percentiles] number of cores (3 [3, 4] versus
4 [3, 4]; P = .47), estimated length of CNB tissue (4.1
[2.5, 6.1] versus 3.7 [2.3, 6.0] cm; P = .09), or target
size (3.3 [2.2, 4.1] versus 3.2 [2.1, 4.0] cm; P = .5;
Figure 1) between biopsy types. There was no association between the target size and the number of core
specimens obtained (r = 0.08; Figure 2).
The proportion of actionable diagnoses with CNB
alone was greater than that with CNB + FNA (83.5%
versus 71.5%; Table 2). However, after controlling for a
history of lymphoma, there was no signiﬁcant difference
in obtaining an actionable diagnosis between CNB versus CNB + FNA (P = .271; Table 3). There was no
signiﬁcant association between achievement of an
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actionable diagnosis and the number of cores
(P = .826) or needle gauge (P = .172, 18 versus
16 gauge; and P = .088, 18 versus 20 gauge).
Of the 578 biopsies, only 3 minor complications
were documented: 2 small hematomas (18-gauge
CNB) and 1 case of left-hand numbness (18-gauge
CNB + FNA), which resolved, presumed related to
lidocaine inﬁltration of the axillary nerve. These ﬁndings correspond to a minor complication rate of 0.5%,
with no major complications.

Discussion
The data from this retrospective study demonstrate
that CNB alone performs as well as CNB + FNA in
achieving an actionable diagnosis, after controlling for
a history of lymphoma. Our study reﬂects clinical
work ﬂow, as the oncologist made the determination
of whether an actionable diagnosis was achieved
through biopsy and pathologic diagnosis, and differs
from other diagnostic yield investigations, which use
lymphoma
subclassiﬁcation
as
the
end
point.7,10,12–14,18,19 This approach is likely more clinically relevant, as the pathologic diagnosis is interpreted within the context of an individual patient. For

example, there may be high clinical suspicion for
transformation of a previously subclassiﬁed lymphoma, which is not reﬂected in the pathologic specimen because of a sampling error. In our study, this
discrepancy would be classiﬁed as not achieving an
actionable diagnosis, whereas if subclassiﬁcation were
the end point, it would be categorized as a successful
case. Because of these differences in study methods,
our results are not directly comparable to other
studies.
Our study demonstrated a greater yield of actionable diagnoses in patients with a history of lymphoma
(82.4%–88.1%) as opposed to those without a known
history (66.4%–68.2%), consistent with the
literature.7,10,13
In our comparison of CNB to CNB + FNA, we
found that the mean age of patients undergoing CNB
Figure 2. Number of cores obtained by target size. Boxes represent the 25th and 75th percentiles, with vertical lines within the
boxes representing the medians, and lines extending from the
boxes indicating the minimum and maximum values. The graph
shows the distribution of the number of cores obtained by either
CNB or CNB + FNA based on the size of the targeted lymph node.
There is no correlation between the number of cores of obtained
and the size of the targeted lymph node (r = 0.08).

Figure 1. Box plot of target size by biopsy type. Boxes represent
the 25th and 75th percentiles, with horizontal lines within the boxes
representing the medians, and lines extending from the boxes indicating the minimum and maximum values. There is no difference in
the size of the targeted lymph node between CNB and
CNB + FNA.

Table 2. Actionable Diagnosis by Biopsy Type
Actionable Diagnosis
No, n (%)
Yes, n (%)
Total, n

CNB
45 (16.5)
228 (83.5)
273

CNB + FNA Total
87 (28.5)
218 (71.5)
305

132
446
578

P

.0006

Statistical signiﬁcance was determined by the χ2 test.
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Table 3. Actionable Diagnosis With or Without History of Lymphoma by Biopsy Type
Actionable
Diagnosis
No, n (%)
Yes, n (%)
Total, n

No History of Lymphoma

History of Lymphoma

CNB

CNB + FNA

CNB

CNB + FNA

Total

P

20 (31.8)
43 (68.2)
63

70 (33.6)
138 (66.4)
208

25 (11.9)
185 (88.1)
210

17 (17.6)
80 (82.4)
97

132
446
578

.271

Statistical signiﬁcance was determined by the Cochran-Mantel-Haenszel test.

alone was older than that of those undergoing
CNB + FNA. We also found that patients with a history of lymphoma were more likely to undergo CNB
alone rather than CNB + FNA. These ﬁndings are
consistent with our institutional practice of performing CNB + FNA rather than CNB alone for new
potential diagnoses of lymphoma in which patients
are often younger than those with established diagnoses who have recurrent disease after treatment.
We found that the number of core specimens
obtained did not affect the actionable yield. This ﬁnding
seems counterintuitive given the general propensity of
pathologists to desire more tissue. Given the retrospective nature of this study, it is difﬁcult to determine with
certainty the reason why more tissue did not result in a
greater yield. The pathology and radiology reports did
not specify the total length of tissue obtained, and it is
possible that our core length estimations were incorrect,
especially if the core specimens were highly fragmented,
a data point that was not available in the radiology
report. However, the number of cores submitted also
did not affect the actionable yield. As the number of
cores obtained was at the discretion of the performing
radiologist, it is possible that more core specimens were
obtained by the radiologist when the core specimens
were fragmented, of a shorter length, or otherwise
thought to be of low quality. It is also possible that
pathologist satisfaction with fewer cores or the method
used by pathology in the review of specimens negated
the impact of a greater number of cores.
Although the large population size is a major
strength of our study, there were several limitations.
First, because of its retrospective design, data points
pertaining to the length and quality of cores were
inaccessible. Second, this study was limited to peripheral lymph nodes and may not necessarily apply to
deeper locations such as retroperitoneal lymph nodes,
sampled under computed tomographic guidance.
Third, the calculated yield of actionable diagnoses did

J Ultrasound Med 2019; 38:581–586

not include failed procedures meant to sample lymphoid tissue, and inclusion of these cases may have
decreased our overall yield but would apply to both
methods of tissue sampling. In fact, no case was
found in which FNA obtained an actionable diagnosis
when the CNB showed no lymphoid tissue.
In patients with a suspected new diagnosis of lymphoma, current practice at our institution is to perform
CNB and FNA concurrently, whereas in cases with a
history of lymphoma, CNB is performed, with or without FNA, at the discretion of the ordering physician and
radiologist. In both groups of patients, performing CNB
alone may decrease the procedure time and cost, potentially leading to improved patient satisfaction while
maintaining a similar diagnostic yield.
Core needle biopsy without FNA of peripheral
lymph nodes provides sufﬁcient tissue to obtain an
actionable diagnosis in new or recurrent lymphoma.
However, discussions with our pathologists reveal
that ﬂow cytometric data from FNA may decrease the
special stains necessary for processing of CNB specimens, potentially improving pathology work ﬂow.
Our institutional practice is to submit FNA for ﬂow
cytometry, but CNB specimens in RPMI solution
could be submitted for this purpose, streamlining the
work ﬂow for both pathology and radiology.
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